New aspects of myeloproliferative neoplasms: COVID-19 and myeloproliferative neoplasms
New aspects of myeloproliferative neoplasms: COVID-19 and myeloproliferative neoplasms
复制标题
骨髓增殖性肿瘤的新方面：COVID-19 和骨髓增殖性肿瘤
DOI：
10.11406/rinketsu.63.647
复制
发表时间：
2022
期刊：
影响因子：
--
通讯作者：
幣 光太郎
中科院分区：
文献类型：
--
作者：
Nishimura K*;Yamazaki H*;Zang W;Inoue D.;幣 光太郎
严重急性呼吸综合征冠状病毒2型（SARS-CoV-2）大流行使血液系统疾病患者的冠状病毒病-2019 （COVID-19）管理成为血液学家新的重要主题。骨髓增生性肿瘤（mpn）患者易感染SARS-CoV-2，并且在COVID-19发病后死亡风险增加。因此，感染预防措施，包括对所有患者接种疫苗，是重要的。感染COVID-19的mpn患者预后较差，其他血液系统恶性肿瘤患者也是如此。mpn的血栓形成特征增加了COVID-19引起静脉血栓形成的风险。根据每个病例发病后的风险调整抗凝治疗。然而，血栓形成的发生率很高，特别是在原发性血小板增多症患者中。此外，骨髓纤维化患者死亡和出血的风险增加。鲁索利替尼治疗存在感染sars - cov -2的风险，感染后突然停药与死亡风险增加有关。新出现的COVID-19证据已迅速反映在现有的治疗建议和指南中。
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has made the management of coronavirus disease-2019 (COVID-19) in patients with hematological disorders a new and important theme for hematologists. Patients with myeloproliferative neoplasms (MPNs) are susceptible to SARS-CoV-2 and are at an increased risk of death after the onset of COVID-19. Thus, infection prevention measures, including vaccination for all patients, are important. Patients with MPNs who have COVID-19 have a poor prognosis, as do patients with other hematological malignancies. The thrombogenic characteristics of MPNs increase the risk of venous thrombosis due to COVID-19. Anticoagulant therapy is adjusted according to the risk of each case after COVID-19 onset. However, thrombosis occurs at a high rate, especially in patients with essential thrombocythemia. Additionally, patients with myelofibrosis have an increased risk of death and bleeding. Ruxolitinib treatment poses a risk of SARAS-CoV-2 infection, and its abrupt discontinuation after infection is associated with an increased risk of death. The emerging evidence of COVID-19 has been quickly reflected in the available treatment recommendations and guidelines.